Summary
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’ Early Development Services group offers expert services to measure abuse potential of investigational drugs by performing human abuse liability (HAL) studies, which are required for drugs that affect the central nervous system, drugs similar to known drugs with abuse potential, and drugs with positive psychoactive effects. This poster discusses what a HAL study is and the challenges posed to study teams and medical writers by the complexity and unique design of these Phase I clinical trials.
Register to download
Human Abuse Liability Studies: Not Your Traditional Phase I Study
You may also be interested in:
Fact Sheet
Central Review Services
PRA's Central Review Services team, unique in the CRO industry, offers lupus-specific expertise in efficacy endpoint data correlation, standardized…
resource
Opportunities in low-level radiocarbon microtracing: applications and new technology
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…
White Paper
Clinical Trials in Children with Impaired Mental Capacity
Download this resource to learn how to conduct studies with patients who lack legal competence and the 4 ethical pillars of medical research.